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Abstract 
Purpose: this study was to design and evaluate effervescent floating tablets with sustained 
release behaviour. Pentoxifylline is a water-soluble model drug with a short half-life, 
consequently developing sustained release preparations would be beneficial. Methods: a 
binary (1:1) mixture of sodium alginate and hydroxyethyl cellulose containing pentoxifylline, 
with either 10% or 20% calcium carbonate or sodium carbonate, was used to prepare floating 
tablets. Results: tablets floated on the surface of the dissolution medium, showed an adequate 
floating lag time, and floated for more than 12 hours. Tablets manufactured from granules with 
20%(w/w) calcium carbonate were promising with respect to their floating lag time (~7min), 
floating duration (>24 hours),  sustained drug release rate, and swelling ability. An in vivo study 
of these promising tablets and a reference solution of pentoxifylline were investigated 
following oral administration of 5.75±0.15mg in rats. Compared with the reference solution, 
the pharmacokinetic parameters changed significantly (p<0.05); the Cmax of the tablets was 
decreased (945.32ng/ml versus 2552.30ng/ml for the solution), while the Tmax and t1/2 were 
prolonged. Conclusion: the study shows that a binary mixture of hydroxyethyl cellulose and 
sodium alginate, together with 20%(w/w) calcium carbonate, offers an exciting opportunity to 
develop sustained release pentoxifylline preparations. 
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Introduction 
Gastroretentive drug delivery systems provide dosage forms with prolonged residence time in 
the stomach and sustained release behaviour, which can improve bioavailability and acting 
locally on the stomach.1,2 Increasing gastric residence time can be achieved either by ﬂoating,3 
high density,4 bioadhesive,5 or expandable systems.6 Floating drug delivery systems are 
designed to have a density lower than that of the gastric fluid, hence they can float for a 
prolonged period of time without affecting the gastric emptying rate.7,8 Floating drug delivery 
systems are classified as either effervescent systems or non-effervescent systems. Non-
effervescent floating drug delivery systems are based mainly on gel-forming or highly swellable 
cellulose type hydrocolloids, polysaccharides, and matrix forming polymers, such as 
polycarbonate, polyacrylate, polymethacrylate and polystyrene.9 However, effervescent 
floating drug delivery systems are based on effervescent components that generate carbon 
dioxide gas due to the presence of acidic gastric fluid. The generated gas bubbles are 
entrapped in a gel layer formed by hydrocolloids that produce an upward motion of the dosage 
form and maintains its buoyancy.10 
Effervescent floating drug delivery systems have been successfully prepared as multi-
particulate dosage forms, such as beads,11 microballoons,12 and microspheres,13 or as single 
unit dosage forms, like tablets and capsules. Floating tablets can be prepared as single or 
double layered dosage forms. In single layer tablets, carbon dioxide generating agents are 
mixed within the tablet matrix;14-16 however, double layered floating tablets can be prepared 
whereby gassing agents are mixed with hydrocolloid and pressed in a separate layer compared 
to that controlling drug release.9 Floating capsules have been shown to float as a result of the 
generation of carbon dioxide that is trapped in the hydrating gel network upon contact with 
the acidic medium.17,18 Inclusion of carbonate gassing agents can provide an alkaline 
microenvironment for a polymer to initiate gel formation6. In addition, liberation of carbon 
dioxide can accelerate hydration of a polymer, which is essential for formation of a bioadhesive 
hydrogel that can assist the remaining of the dosage form inside the stomach.19 
Carbonate gassing agents have been previously used to enhance tablets floating behaviour, 
such as sodium bicarbonate20 (mainly used in floating tablet formulations) and calcium 
carbonate.21 Although sodium carbonate decomposes upon contact with acids in the presence 
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of water to produce carbon dioxide and effervescence,22 there is a lack of information about 
its usage in this field of research. 
The aim of this study was to develop and evaluate a swellable, floatable, gastroretentive drug 
delivery system utilising an effervesce mechanism. Tablets were based on a binary (1:1) gel-
forming polymer mixture of hydroxyethyl cellulose and sodium alginate, and calcium carbonate 
or sodium carbonate gas generating agents. Pentoxifylline was used as a model drug since it 
has a short half-life of 1–2 hours,23 high density,24 and is highly soluble in water (191 mg/mL at 
37°C).25 The variables that may affect drug release and floating properties were investigated, 
such as wet granulation (to compare effects of powders versus those of granules), type and 
the ratio of gas-forming agent. 
Materials and Methods 
Materials 
Calcium carbonate, sodium carbonate, sodium alginate (15–20 cP), and pentoxifylline were 
supplied by Sigma-Aldrich (UK), silicified microcrystalline cellulose (Prosolv® 90) was obtained 
from JRS Pharma (Germany), and magnesium stearate was supplied by MEDEX (UK). 
Emitrecitabine, ammonia, formic acid, methanol, and ACE 5 C18 columns were supplied by the 
Jordan Centre for Pharmaceutical Research (Jordan). Hydroxyethyl cellulose (Natrosol 250-HHX) 
was generously provided by Ashland (USA).  
Powders and granules containing the pentoxifylline preparation   
Powder mixture compositions for the preparation of tablets are shown in Table 1. Powder 
blends were prepared using a binary (1:1) mixture of hydroxyethyl cellulose and sodium 
alginate gel forming agents. Prosolv® 90 was used as a filler to enhance the compression 
process, calcium carbonate or sodium carbonate was added as a gas-forming agent at 0%, 10% 
or 20% (w/w) concentration, and pentoxifylline was used as a model drug. All ingredients were 
passed through 180 μm sieve before mixing; sodium alginate was passed through a 350 μm 
sieve, a size suitable for tablet compression. Pentoxifylline was formulated as floating tablets 
in a previous research by same authors20, however a different gassing agent (sodium 
bicarbonate) was used in the previous study20.  
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Table 1 Composition of prepared tablets 
Ingredients F1 (mg) F2 (mg) F3 (mg) F4 (mg) F5 (mg) 
Pentoxifylline 60 60 60 60 60 
Hydroxyethyl cellulose 70 70 70 70 70 
Sodium alginate 70 70 70 70 70 
Prosolv® 90 50 50 50 50 50 
Calcium carbonate  27.5 62.5    
Sodium carbonate   27.5 62.5  
Magnesium stearate (0.5%) 1.4 1.6 1.4 1.6 1.3 
Total weight 278.9a 314.1a 278.9a 314.1a 251.3 
a Difference in weight due to raising gassing agent content from 10% to 20% w/w.                                                                                                                                  
 
A turbula mixer (Glen Creston Ltd, UK) set at 60 rpm, with a stainless steel mixing vessel, was 
used to mix the powders for 10 minute. A wet granulation process was used to modify powder 
flowability and to facilitate automatic compression of the powder; powder mixtures were 
wetted with 0.5% w/w of water and mixed for 10 minutes using a Kenwood ChefKneader 
(Thorn Domestic Appliances Ltd, UK) before being manually passed via a 1,000 μm sieve. 
Prepared granules were dried at 60°C overnight using a drying oven (SciQuio Ltd, UK),26 and 
then dried granules ≤853 μm were used.   
Preparation of floating tablets  
To evaluate the effect of gassing agent concentrations on tablet porosity, floating capacity, 
swelling, erosion and dissolution behaviours, pentoxifylline tablets were automatically pressed 
(for granulated powders) using a single-punch tableting machine (Type 3, Manesty Machines 
Ltd, UK) equipped with flat-faced punches (9.60 mm), and the compression speed was 85 RPM. 
The compaction pressure (Table 3) was adjusted by decreasing the distance between punches 
to produce tablets with a hardness level of 49–54 N, as measured using a hardness tester 
(Model 2E/205, Schleuniger & Co., Switzerland). All the tablets resulting from the F1, F2, F4, 
and F5 formulations were successfully pressed automatically. However, the F3 formulation 
could not be pressed automatically at the required hardness level (49–54 N), hence these were 
pressed manually; the required granule weight was fed directly from the hopper into the die 
of the single-punch tableting machine and compacted manually. 
In order to compare between tablets before and after granulation, in other words to 
investigate the possible effect of the wet granulation process on tablet porosity, floating 
capacity and dissolution behaviour, a group of manually pressed tablets were prepared from 
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powder blends before granulation, where the required powder mixture was weighed and fed 
manually into the die of the single-punch tableting machine to produce the desired tablets.  
Evaluation of the formulated powders and granules: 
Flowability test   
The tapping apparatus (Copley JV1000, UK) was used. Bulk and tapped densities were 
calculated as the ratio of the powder weight to the related powder volume, and Carr’s 
compressibility index (CI) was calculated using equation (1):27 
𝐶𝐼 = (
𝑇𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦−𝐵𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑇𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
) x 100      (Eq. 1) 
 
Characterisation  of floating tablets 
Tablets originally prepared from granules were evaluated for tablet friability, hardness, weight 
uniformity, porosity, drug content uniformity, floating capacity, swelling and erosion, and 
dissolution. Tablets prepared from powder mixtures were evaluated only for porosity, floating 
capacity, and dissolution, as these tablets had been compacted manually. Tablet quality control 
tests were conducted in accordance with the British Pharmacopoeia (BP) specifications.28  
Tablet apparent density, tensile fracture strength and porosity  
Tablet thickness (t) and diameter (D) were recorded using a calliper scale (Moore and Wright 
Sheffield England Metric, UK). Tablet hardness (P), weight (w), and the circular constant (π) 
were used to calculate the apparent density (Ad) of the tablets by equation (2)18 and Tablet 
tensile fracture strength (σt) by equation (3)29 
𝐴𝑑 (
𝑔
𝑐𝑚3
) =
𝑤
(
𝐷
2
)
2
×𝜋×𝑡
        (Eq. 2) 
𝜎𝑡 =
2𝑃
𝜋𝐷𝑡
          (Eq. 3) 
Mean values ± SD are presented. 
Tablet porosity ε, was calculated using equation (4):30 
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𝜀 = [1 − (𝜌𝑡𝑎𝑏𝑙𝑒𝑡 − 𝜌𝑡𝑟𝑢𝑒)] × 100       (Eq. 4) 
Where ρtablet is the tablet’s apparent density and ρtrue is the true density of the powder mixture 
or granule sample measured using a multipycnometer (MVP-D160-E, Quantachrome 
Instruments, USA). A sample of 1.8 g was used, the helium pressure was set to 17 psi, and the 
difference in helium pressure before and after sample loading was recorded to determine the 
true volume of the samples. Mean of five replicates ± SD was presented. 
In vitro drug release test  
Drug release was performed using USP dissolution apparatus II (Erweka GmbH, Germany) at 
37°C±0.5°C, and a paddle speed of 50 rpm.28 Tablets were inserted into 900 mL 0.1 M HCl (pH 
1.2) as a simulated gastric fluid without the presence of gastric enzymes. The test was 
accomplished in triplicate and mean values ± SD are presented.  
Tablet floating capacity 
Floating capacity was investigated under the same conditions and using the same apparatus as 
for the in vitro studies. The time taken for tablets to show up and remain on the dissolution 
medium surface (floating lag time) and the period of time that the tablets constantly floated 
on the dissolution medium surface (floating duration) were determined visually throughout 
the drug release studies,15 and mean ± SD values are presented. 
Swelling and erosion studies 
The initial weights of three randomly chosen tablets were recorded. Dissolution medium 
uptake (DMU) and mass loss (ML) percentage of the tablets were determined using USP 
Dissolution Apparatus II (Erweka GmbH, Germany) under similar conditions to the drug release 
study. Tablets were withdrawn using a spoon spatula from the medium at 0.5, 1, 2, 4, 6, 8, 12, 
and 24 hours. Excess liquid present on the surface of tablets  was carefully removed using a 
filter paper and the tablets were weighed and then dried at 60°C in a drying oven until a 
constant dry weight was achieved. Swelling rate and mass loss rate were calculated by 
equations (5) and (6):31 
%𝐷𝑀𝑈 = (
𝑊𝑤−𝑊𝑖
𝑊𝑖
) × 100       (Eq. 5) 
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%𝑀𝐿 = (
𝑊𝑖−𝑊𝑑
𝑊𝑖
) × 100       (Eq. 6) 
 
Where Wi is the initial weight of the tablet, Ww is the wet weight of the tablet, and Wd is the 
dry weight of the tablet and mean values ± SD were presented. 
In vivo pharmacokinetic study 
Twelve male albino rats weighing 180 ± 20 g were provided by Applied Science Private 
University. The animals were kept in the animal house at an ambient temperature (25 ± 1 °C) 
with a 12 h dark and 12 h light cycle. The animals were fed a pellet diet and had access to water 
ad libitum. The experimental protocol was approved by the Research Ethics Committee 
(Sunderland University), and all methods were conducted according to the University of 
Applied Science Private University guidelines.  
Pentoxifylline tablets (weighing 30±1 mg) of F2 formulation were pressed manually (for 
granulated powders) using a single-punch tableting machine (Type 3, Manesty Machines Ltd, 
UK) equipped with flat-faced punches (4.00 mm), and the compression force was adjusted to 
produce tablets with a hardness level of 20 ± 1 N. An aqueous solution of pentoxifylline (2.88 
mg/ml) was prepared as a reference. 
Rats were randomly divided into two groups and fasted for about 12 h prior to the experiment 
but had free access to water. The first group received the oral tablets, and the second group 
received the oral reference solution. The preparations (tablets and solution) were loaded 
directly into stomach by intra-gastric gavage at a single dose of 5.75±0.15 mg. Blood samples 
were collected using the tail-bleeding technique into a 0.5ml mini-collect tube (K3E K3EDTA) 
at 0.5, 1, 2, 4, 6, 8, 12 and 24 hours, then subjected to centrifugation for 5 min at 13000 rpm 
(Model M-24, Boeco, Germany) and aliquots of plasma frozen at − 20 °C before analysis.  
Plasma samples (0.2 ml) were mixed with 50 μl of an internal standard (20μg/ml of Emitrecitabine) 
by vortexing, before adding 0.55 ml of methanol and mixing, then subjecting the mixture to 
centrifugation for 10 min at 14000 rpm using a centrifuge (Model 5417C, Eppendorf - Nrtheler - 
Hinz GmbH, Germany). 2 μl was directly injected into a HPLC-MS/MS system (Model 1200, 
Agilent Technologies Co., Ltd., Santa Clara, USA), which was equipped with a mass 
spectrometer (Model API 4000, SCIEX, Toronto, Canada).  
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In this pharmacokinetic study, the maximum plasma concentration (Cmax) and time to reach 
this concentration (Tmax) were obtained by actual observations of the plasma concentration-
time data. The elimination rate constant (ke) was calculated from the slope of the linear 
terminal line of the logarithmic plasma concentration-time data, and the half-life (t1/2) was 
calculated by equation (7):32 
𝑡1
2⁄
=
0.693
𝑘𝑒
         (Eq. 7) 
The area under the curve (AUC0-t) was calculated by using the trapezoidal rule from 0 to 24 h, 
and the area under the curve from zero to infinity (AUC0-∞) was calculated from (AUC0-t) plus 
the extrapolated portion Cp/ke by equation (8): 1  
𝐴𝑈𝐶0−∞ = 𝐴𝑈𝐶0−𝑡 +
𝐶𝑝𝑡
𝑘𝑒
       (Eq. 8) 
Where Cpt is the plasma drug concentration observed at time t. All data are presented as the 
mean value ± SD.  
The relative bioavailability values (F) were calculated by equation (9):32 
𝐹 =
𝐴𝑈𝐶𝑡𝑎𝑏𝑙𝑒𝑡
𝐴𝑈𝐶𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
×
𝐷𝑜𝑠𝑒𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
𝐷𝑜𝑠𝑒𝑡𝑎𝑏𝑙𝑒𝑡
                                                                     (Eq. 9) 
 
Statistical analysis 
The statistical software package, SPSS 22 (SPSS Inc., Chicago, USA) was used to perform the 
statistical analyses by applying the paired-sample t-test and one-way analysis of variance, 
depending on the type of data. A P-value of <0.05 was considered significant. 
Results and Discussion 
Flowability for powders and granules  
Table 2 shows the results for the CI values for all the formulations before and after granulation. 
The CI values decreased significantly (p<0.05) following granulation for all the prepared 
formulations (F1-F5, Table 2), revealing better flow properties of the granules compared to the 
powder mixtures.33 
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Table 2 Properties of powder mixtures and granules of F1-F5 formulations.  
Formulation Origin of prepared tablets       
 powder mixtures  Granules  
 Bulk density 
(g/cm3)a 
Tapped 
density 
(g/cm3 )a  
True density  
(g/cm3)b  
Carr’s Index a Bulk 
density 
(g/cm3)a 
Tapped 
density 
(g/cm3 )a  
True density  
(g/cm3)b  
Carr’s Index a  
F1 0.502±0.02 0.683±0.00 1.35±0.02 26.57±2.53 0.531±0.01 0.637±0.01 1.43±0.02 16.63±1.69 
F2 0.475±0.02 0.677±0.00 1.46±0.01 29.81±3.09 0.539±0.01 0.644±0.01 1.54±0.01 16.33±0.43 
F3 0.501±0.01 0.727±0.00 1.47±0.02 31.06±1.58 0.526±0.00 0.621±0.01 1.47±0.01 15.26±1.85 
F4 0.541±0.00 0.741±0.01 1.40±0.03 27.02±1.32 0.486±0.01 0.585±0.01 1.49±0.02 16.83±2.05 
F5 0.492±0.01 0.700±0.02 1.46±0.02 29.67±1.60 0.455±0.01 0.537±0.01 1.40±0.03 15.29±1.67 
a The data represent mean ± SD of three determinations. 
b The data represent mean ± SD of five determinations. 
  For formulations composition refer to Table 1. 
Evaluation of floating tablets 
Tablet apparent density and porosity 
For floating drug delivery systems it is important that density is <1.00 g/cm3 in order to initiate 
buoyancy on the release medium.8 Upon water uptake, chains of hydrophilic polymers move 
apart from each other, resulting in both weight and volume increases. Although, this will 
reduce the density of the swelled matrix, the rate of release medium uptake depends upon the 
matrix porosity level. The apparent density and porosity results of the tablets were used to 
evaluate the magnitude of the different formulation factors (wet granulation, type and ratio of 
gas forming agents) on the prepared tablets. 
The apparent densities of all the prepared tablets before and after granulation are shown in 
Figure 1. The granulation process caused a significant (P<0.05) increase in tablet apparent 
density for F1, F2, and F3 formulations, which was not observed for F4 and F5 formulations. 
The granulation process might enhance the elastic recovery of alginate molecules after 
compression, which justifies the results for the F5 (0% w/w gassing agent) formulation, where 
tablet thicknesses after granulation increased (Table 3) whilst the apparent density decreased 
(Figure 1). It has been reported that the chemical composition of alginates affects their 
compression behaviour, where alginates with low guluronic acid content behave more 
elastically than alginates with low mannuronic acid content. In this study the ratio of 
mannuronic acid to guluronic acid is 1.56. Furthermore, the plasticity of potassium alginates is 
higher than that of sodium alginates, though, alginates deform elastically.34 This is in 
agreement with the apparent density result for F4 (20% w/w sodium carbonate) and complies 
with the sodium bicarbonate floating tablet results published in our previous study.20  
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Figure 1: Apparent density of F1, F2, F3, F4, and F5 tablets before granulation and after granulation. 
The data represents the mean ± SD of six determinations. For formulation composition, refer to Table 
1. 
 
The apparent density of the F3 (10% w/w sodium carbonate) tablets increased after 
granulation. This formulation was pressed manually, and the longer contact time between 
powder/granules and punches of the tableting machine might overcome the alginate elastic 
recovery following compression. Additionally, it has been reported that the amount of stress 
developed at the points of local deformation depend upon several factors, such as physical 
properties of the material, force magnitude, rate of application, and contact time.35    
The tablet thicknesses of F1 (10% w/w) and F2 (20% w/w) calcium carbonate based tablets, 
decreased after granulation (Table 3). This may be explained by the good compressibility of 
calcium carbonate that might overcome the effect of sodium alginate elastic recovery 
following compression due to the granulation process; this also explains the benefits of using 
calcium carbonate in effervescent floating tablets. As shown in Table 3, lower compaction 
pressure were applied to prepare calcium carbonate based tablets (F1 and F2) with higher 
tablet tensile fracture strength (Table 5) and lower porosity percentages (Figure 2) in 
comparison with the other tablets.   
Moreover, changing the calcium carbonate concentration from 10% to 20% (w/w) significantly 
increased (P<0.05) the apparent density of all the tablets prepared from powder mixtures or 
granules. However, raising the sodium carbonate concentration to 20% (w/w) significantly 
increased (P<0.05) the apparent density of only those tablets prepared from powder mixtures. 
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This might be justified by the high specific gravities of calcium carbonate and sodium 
carbonate, which are 2.7036 and 2.53,22 respectively, which is in agreement with the results for 
sodium bicarbonate published in our previous study.20 
A non-significant (P>0.05) decrease in the apparent density of tablets prepared from granules 
due to changing the sodium carbonate concentration from 10% to 20% (w/w) was noted. As 
mentioned above, the manual pressing of the F3 (10% w/w sodium carbonate) formulation 
may enhance a reduction in the tablet thickness, with a higher ratio than that of F4 (20% w/w 
sodium carbonate) tablets, which could justify this reduction in density. 
Table 3 Properties of F1-F5 formulation tablets before granulation and after granulation. 
Formulation Origin of prepared tablets     
 Before granulation   After granulation  
 Compaction pressure 
(kN) 
Tablet weight (g)a Tablet thickness (cm) a Compaction 
pressure (kN)  
Tablet weight (g) a Tablet thickness (cm) a 
F1 25.00 0.277±0.00 0.299±0.01 30.10 0.272±0.00 0.285±0.02 
F2 26.00 0.310±0.00 0.326±0.01 31.20 0.309±0.00 0.311±0.01 
F3 26.50 0.278±0.00 0.298±0.00 28.50 0.279±0.00 0.286±0.01 
F4 26.25 0.312±0.00 0.326±0.01 28.25 0.315±0.00 0.329±0.08 
F5 28.00 0.275±0.00 0.305±0.01 31.00 0.280±0.00 0.318±0.02 
a The data represent mean ± SD of six determinations. For formulations composition refer to Table 1. 
 
The tablet porosity percentages of F1, F2, F3, F4, and F5 formulations are presented in Figure 
2. The granulation process significantly increased (P<0.05) the porosity of the F1 and F4 tablets, 
and non-significantly (P>0.05) the porosity of the F2 tablets. In contrast, the porosity 
significantly decreased (P<0.05) in the F3 and F5 tablets due to the granulation process.  
 
 
Figure 2: Porosity percentage of F1, F2, F3, F4 and F5 tablets before and after granulation. The data 
represents the mean ± SD of five determinations. For formulation composition, refer to Table 1. 
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It has been demonstrated in a previous study of cross-linked drug alginate granules that 
increasing the water binder volume decreases porosity during the wet massing stage.37 This 
supports the results for the F5 (0% w/w gassing agent) formulation, where the granulation 
process reduced the tablet porosity in comparison to tablets with no gassing agents. However, 
tablet porosities of calcium carbonate based formulations (F1 and F2) increased following 
granulation, which may be related to the insolubility of calcium carbonate in water36 that could 
enhance the formation of voids between adjacent molecules during the wet massing stage 
with water. In contrast, sodium carbonate as a gassing agent is a water-soluble material,22 
which might form a homogenous mass with the hydrophilic polymeric binary mixture during 
the wet massing process. This probably accounts for the tablet porosity reduction at 10% (w/w) 
in the F3 formulation after the granulation process. Moreover, this is in agreement with the 
results of our previous study of sodium bicarbonate20 which is also water-soluble.38 However, 
the significant (P<0.05) elevation in porosity observed for the F4 tablets could be explained by 
the hygroscopic properties of sodium carbonate, whereby one mole of sodium carbonate can 
gradually absorb one mole of water on exposure to air.22 Raising the sodium carbonate 
concentration means that more water molecules may be absorbed and evaporated through 
the granulation process, and the total porosity will be increased.   
Increasing the calcium carbonate concentration from 10% (w/w) (F1) to 20% (w/w) (F2) 
significantly increased (P<0.05) the porosity percentage of tablets prepared from both powder 
mixtures and granules. A significant (P<0.05) increase in porosity was noted when the sodium 
carbonate concentration was raised from 10% (w/w) (F3) to 20% (w/w) (F4) in tablets prepared 
from granules; however, the porosity significantly decreased (P<0.05) for tablets prepared 
originally from powder mixtures. It has been reported that calcium carbonate mainly 
undergoes fragmentation when compressed;39 which will produce high porosity tablets at 
comparable compaction pressure due to its high yield pressure.40 This may explain the increase 
in tablet porosity due to the change in calcium carbonate concentration in tablets prepared 
from either powder mixtures or granules. 
For tablets prepared originally from powder mixtures, raising the sodium carbonate 
concentration from 10% (w/w) (F3) to 20% (w/w) (F4) could enhance more voids between 
molecules being filled after compression, which might reduce porosity. This also is in 
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agreement with the results of our previous study of sodium bicarbonate as a gassing agent.20 
However, the significant (P<0.05) increase in the porosity value of tablets prepared originally 
from granules could be explained by the hygroscopic properties of sodium carbonate, as 
mentioned earlier.  
Tablet floating capacity 
Floating drug delivery systems aim to keep floating for a long period of time on the release 
medium of the stomach without affecting the gastric emptying time. Normally, in humans the 
average gastric emptying time takes 2-3 hours during fasting and a longer time in fed 
conditions. Moreover, all undigested materials are normally emptied out of the stomach and 
down the small intestine at the end of the gastric emptying process.41 However, it is important 
for floating tablets to avoid premature sweeping from their major absorption zone of the 
stomach and upper intestine, which can be managed by achieving the least possible lag time, 
and longer floating duration.  
Table 4 presents the floating capacities of all the formulations before and after granulation. All 
the tablets (F1-F5) were tested for floating capacity under the same conditions and using the 
same apparatus for the in vitro studies. The F5 tablets had no floating capacity, as they do not 
contain any gassing agent. Both calcium carbonate and sodium carbonate as gassing agents 
enhance the floating behaviour of the formulated tablets; carbon dioxide is generated by 
reaction with the acidic dissolution medium (0.1M HCl) and entrapped in the formed gel layer 
around the swollen tablets.  
Table 4: Floating capacity of F1-F5 formulations before granulation and after granulation. 
Formulation Floating lag time (min) 
  
 Total floating duration (h) 
Origin of tablet  Origin of tablets 
Before granulationa After 
granulationa 
  Before granulation After 
granulation 
 
F1 0.32±0.07 21.81±4.00   Complete disintegration > 5  
F2 0.21±0.04 6.93±1.03   Complete disintegration > 24  
F3 1.88±0.65 6.95±0.91   > 12 > 12  
F4 4.20±0.73 8.27±1.25   > 24 > 24  
F5 Complete disintegration No floating   Complete disintegration No floating  
 aThe data represent mean ± SD of three determinations. For formulations composition refer to Table 1 
 
The granulation process caused a significant increase (P<0.05) in the lag time for all the floating 
tablets (F1-F4) compared to tablets prepared from powder mixtures before granulation (Table 
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4). A complete disintegration effect was seen in tablets prepared from powder mixtures based 
on calcium carbonate as the gassing agent (F1 and F2), whereby tablets rapidly moved in an 
upward motion and disintegrated on the surface of the dissolution medium. All the tablets 
based on sodium carbonate as the gassing agent (F3 and F4), either prepared originally from 
powder mixtures or granules, did not show any disintegration behaviour. This disintegration 
behaviour might be justified by the stronger effervescence activity of calcium carbonate 
compared to sodium carbonate, which ruptured the tablet structure of F1 and F2 formulations 
prepared from powder mixture (Table 4). During the granulation process, liquid bridges of 
adhesives, like hydroxyethyl cellulose, are formed between particles during the wet massing 
step and these harden due to the drying step.42 This could make the internal structure of the 
tablets much more resistant to the disintegration effect of the calcium carbonate 
effervescence reaction, and provide sufficient time for swelling and gel layer formation. 
However, the absence of the disintegration behaviour in F3 and F4 tablets prepared from 
powder mixtures could be explained by the better ability of sodium carbonate compared to 
calcium carbonate to provide an alkaline microenvironment for the polymer to initiate gel 
formation.6 It has been recorded that a 1% (w/v) aqueous solution of sodium carbonate 
generates a pH of 11.4 at 25°C22, while a 10% (w/v) aqueous dispersion of calcium carbonate 
produces a pH of 9.0.36  
The increase in lag time results for F3 (10% (w/w) sodium carbonate) tablets after granulation 
might be due to the reduction in porosity. Although the porosity level of the F4 (20% (w/w) 
sodium carbonate) tablets increased due to the granulation process, as mentioned earlier, the 
floating lag time also increased. The increase in the porosity level might enhance rapid contact 
between the gassing agent and the acidic medium, but it also accelerates the escape of 
liberated gas bubbles from the matrix structure before the formation of a coherent gel layer 
around the tablet, which might delay the floating process.  
Increasing the calcium carbonate concentration from 10% (w/w) (F1) to 20% (w/w) (F2) in 
tablets prepared originally from powder mixtures decreased the lag time non-significantly 
(P>0.05), which may be due to the disintegration behaviour of these tablets. Moreover, a 
significant (P<0.05) reduction in the floating lag time was noted in tablets prepared originally 
from granules when the calcium carbonate level was increased from 10% to 20% (w/w). This 
in agreement with the results of our previous study of sodium bicarbonate where increasing 
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the gassing agent content available for an acidic medium enhances the efficiency of the 
effervescence reaction, which will be represented by a shorter floating lag time20. Changing 
the sodium carbonate concentration from 10% (F3) to 20% (w/w) (F4) increased the measured 
lag time non-significantly (P>0.05) in all the tablets. The ability of sodium carbonate to generate 
an alkaline microenvironment to accelerate swelling and gel formation may reduce the 
dissolution medium entrapment rate and the quantity of acidic medium available for the 
effervescence reaction. This means that raising the sodium carbonate level to 20% (w/w) will 
increase tablets density, as mentioned earlier, and more time will be taken to move the tablets 
upward. 
Table 4 shows the floating duration results for all the tablets. As mentioned above, tablets 
based on calcium carbonate as the gassing agent, F1 and F2 tablets, originally prepared from 
powder mixtures showed complete disintegration behaviour. However, due to the granulation 
process, F1 (10% w/w) tablets floated for >5 hours, while F2 (20% w/w) tablets floated >24 
hours due to the high gassing agent reservoir available for the floating process. The granulation 
process did not cause any difference in floating duration for F3 and F4 tablets based on sodium 
carbonate as the gassing agent, where >12 hours and >24 hours were recorded, respectively. 
This could be related to the absence of the disintegration effect due to the ability of sodium 
carbonate to generate an alkaline microenvironment to accelerate gel formation; however, 
the longer floating duration may be related to the high gassing agent reservoir during the test.  
This complies with the results of our previous study of sodium bicarbonate, where a 20% (w/w) 
gassing agent concentration was found to be more effective than a 10% (w/w) concentration 
in keeping tablets on the surface of the dissolution medium for a longer duration of time.20 
Tablet friability, hardness, weight uniformity and drug content uniformity  
The good flow properties of the granules which facilitate their automatic pressing made them 
more suitable to benefit the pharmaceutical industry, therefore, only the tablets prepared 
from the granules were subjected to friability, hardness weight uniformity and drug content 
uniformity tests. Results for hardness (N), tablet tensile fracture strength (MPa), friability (%), 
average weight (g), and average drug content (mg) of all prepared tablets are presented in 
Table 5. All tablets for the F1, F2, F4, and F5 formulations were successfully pressed 
automatically, while those for the F3 formulation were pressed manually. 
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Table 5 Properties of pentoxifylline tablets prepared from granules of F1- F5 formulations. 
Formulation Hardness (N)a Tablet tensile 
fracture strength 
(MPa) 
Friability (%) Tablet weight (g)b Drug content (mg)a 
F1 51.98±0.16 1.21 0.96 0.305±0.00 61.22±0.57 
F2 53.94±0.40 1.15 1.34 0.343±0.00 61.78±1.28 
F3 50.03±0.27 1.16 1.16 0.299±0.00 58.34±1.81 
F4 52.96±0.75 1.06 0.89 0.315±0.00 56.91±2.12 
F5 49.03±0.52 1.02 0.79 0.296±0.00 69.15±0.80 
 
a The data represent mean ± SD of 10 determinations. 
b The data represent mean ± SD of 20 determinations. For formulations compositions refer to Table 1. 
It has been reported in some studies that the hardness of tablets prepared from a mixture of  
two materials can be predicted from the hardness of tablets prepared from each of these 
materials, as a linear relationship can be drawn for the composition of the mixture.43,44 Tablet 
hardness has been shown to exceed the hardness of tablets prepared from individual 
materials,45,46 whilst in other studies it has been lowered compared to that of the individual 
components.47,44   
F1 and F2 formulations using calcium carbonate were pressed successfully, and the good 
bonding capacity under compression of calcium carbonate40 and its role as a filler in 
pharmaceutical formulations36 probably justifies this. However, although pressing sodium 
carbonate alone shows good bonding capacity,48 tablets containing sodium carbonate at 10% 
(w/w) (F3) could not be pressed automatically, although increasing the concentration to 20% 
(w/w) (F4) overcame this issue, and tablets were successfully pressed. Generally, this suggests 
that compressibility of these floating formulations (F3 and F4) is dependent by the 
concentration of sodium carbonate. F5 tablets without any gassing agent were successfully 
pressed at the required level of hardness (49–54 N). However, the granulation process might 
enhance the elastic recovery of alginate molecules following compression, which could explain 
the inability to prepare tablets based on sodium bicarbonate as the gassing agent even at a 
higher level (59–64 N) of hardness following granulation as shown in our previous study.20 In 
addition, it has been reported that sodium bicarbonate has a lower bonding capacity than 
sodium carbonate48 and calcium carbonate.40 Hence, it is worth testing sodium carbonate and 
calcium carbonate as gassing agents, as per this study, especially as the available information 
in the literature on using them in floating tablets is inadequate. 
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All the prepared tablet results (Table V) comply with BP specifications28 with respect to weight 
and drug content uniformity tests. For the friability test, there were no signs of cracked, split, 
or broken tablets throughout the test. Additionally, the results of the F1, F4, and F5 
formulations fit the BP limits, as the tablets had friability values less than 1%;28 however, the 
results for the F2 and F3 formulations exceeded the BP limit of friability at 1.34% and 1.16%, 
respectively. Drug content was found to be in the range of 85%-115%. 
In vitro drug release studies 
Dissolution profiles of all the tablets are shown in Figures 3 and 4. Figure 3 relates to tablets 
prepared from powder mixtures, and F1, F2 and F5 tablets showed only a small difference 
between their drug release results due to their complete disintegration behaviour. However, 
F3 and F4 tablets, which contain sodium carbonate, did not show any disintegration behaviour. 
As mentioned earlier, calcium carbonate may show higher effervescence behaviour than 
sodium carbonate, but the ability of sodium carbonate to generate an alkaline 
microenvironment to accelerate swelling and gel formation is better than that of calcium 
carbonate. Consequently, an insufficient gel layer might lead to partial or complete tablet 
disintegration. 
 
Figure 3: Percentage drug release for F1, F2, F3, F4, and F5 tablets prepared originally from powder 
mixtures in 0.1 M HCl medium. The data represents the mean ± SD of three determinations. For 
formulation compositions, refer to Table 1. 
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Figure 4:  a Percentage drug release for F1, F2, F3, F4, and F5 tablets prepared originally from granules 
in 0.1 M HCl medium. The data represents the mean ± SD of three determinations. For formulation 
compositions, refer to Table 1.b: Floating process of a F2 tablet (marked with a circle) during drug 
release. 
 
Figure 4a shows the drug release rate of tablets prepared from granules and Figure 4b reveals 
the floating of F2 tablets, as an example, a floating lag time was ~ 7 minutes and tablets kept floating 
for > 24 hours. The effect of the granulation process on drug release rate from F1-F5 tablets 
reveals that the granulation process extended the drug release rate for all the prepared tablets; 
this effect was significant (P<0.05) at all the time points in F1, F2, and F5 formulations except 
at the time point 12 hours in F1 and F2 where the effect was not significant (P>0.05). For F3 
and F4 formulations, the granulation process did not cause a significant (P>0.05) decrease in 
the drug release rate except at the initial time points (0.5-2 hours) in F4 formulation where 
P<0.05. 
The granulation process makes F1 and F2 tablets more resistant to rupture due to calcium 
carbonate effervescence behaviour and provides sufficient time for swelling and gel layer 
formation to control the drug release process. The F5 formulation results comply with those 
of Mukhopadhyay et al.,37 where increasing the water binder volume decreased the porosity 
during the wet massing stage, and this reduction delayed the dissolution media entrapment 
through the matrix at an early stage of the dissolution test, which decreased the drug release 
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process. Generally, the insignificance (P>0.05) effect of the granulation process on of F3 and 
F4 tablets could be explained by the high alkalinity of sodium carbonate as the gassing agent, 
which may justify the ability of the tablets either before or after granulation to swell at a similar 
rate. Although the porosity of the F4 tablets increased after granulation, as mentioned earlier, 
it has been proposed that dissolution medium can pass through tablet surface pores to initiate 
gel layer formation through the swelling process.49 The formed gel will block the liquid filled 
pores in less than 15 minutes, after which water will be primarily transported through the 
created coherent gel layer.50 This swelling rate could control the drug release rate and might 
justify the insignificant (P>0.05) effect of granulation. 
There was a non-significant (P>0.05) effect of raising the concentration of calcium carbonate 
as the gassing agent on the rate of drug release for tablets prepared originally from powder 
mixtures except at 0.5 hour time point where P<0.05, as shown in Figure 3, which might be 
due to the complete disintegration behaviour of the tablets; however, the effect was significant 
(P<0.05) at the initial time points (0.5-2 hours) in tablets prepared originally from granules 
(Figure 4a). Increasing the calcium carbonate concentration from 10% to 20% (w/w) increases 
pore formation in the formed gel layer around tablets due to the entrapped gas bubbles, and 
this leads to higher drug release rate. In contrast, increasing the sodium carbonate 
concentration caused a non-significant (P>0.05) increase at all the time points in the rate of 
drug release from tablets prepared originally from powder mixtures (Figure 3) as well as from 
granules (Figure 4a) except at time points 1 and 2 hours in tablets prepared originally from 
powder mixtures where P<0.05. This is in agreement with the previous justification of the 
effect of sodium carbonate alkalinity on the swelling behaviour of tablets.  
The effect of adding a gassing agent on the drug release rate of the tablets prepared originally 
from powder mixtures or granules was evaluated by comparing the results for F5 (0% w/w 
gassing agent) tablets with other formulations. Adding calcium carbonate at both 
concentrations caused high drug release rate due to the liberation of carbon dioxide bubbles. 
Generally, the effect was not significant (P>0.05) at all the time points for tablets prepared 
originally from powder mixtures due to the disintegration behaviour in the F1, F2, and F5 
tablets. However, for tablets prepared originally from granules, the increase in the drug release 
rate was not significant (P>0.05) at 10% (w/w) calcium carbonate, and significant (P<0.05) at 
20% (w/w) calcium carbonate at all the time points except at 12 hours at 10% (w/w) calcium 
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carbonate where P<0.05. In contrast, adding sodium carbonate as the gassing agent at 10% 
(F3) and 20% (F4) (w/w) decreased the drug release rate compared to that for the non-floating 
(F5) tablets of both powder mixtures and granules origin. Generally, the effect at all the time 
points was not significant (P>0.05) except for tablets prepared from powder mixtures, where 
the F5 tablets showed complete disintegration behaviour.  
As mentioned earlier, although F3 and F4 tablets floated >12 and >24 hours, respectively (Table 
4), however, their DMU results were almost the same due to the alkalinity of sodium 
carbonate, which may justify the non-significant difference in their drug release rate.  
The results of  drug release rate from F2 and F4 floating tablets (floated for >24 hours) were 
compared with release profiles of sustained release pentoxifylline market products as reported 
by Popescu et al.,51 who investigated the in vitro performance of several pentoxifylline 
commercial products. One of these products was based on hydroxyethyl cellulose while the 
others were formulated with hydroxypropylmethyl cellulose.  The mean in vitro dissolution 
profiles indicated similar release rates of all tested samples; the release rates were not more 
than 20 % in the first hour, less than 30% at 2 hours, and all products had less than 60% release 
at 6 hours. Those results were less than that obtained from F2 and more than that from F4 
(Figure 4a), meaning that the designed floating tablets from this current study can control the 
performance of the formulations based on the composition.   
Swelling and erosion studies 
Figure 5a shows the % DMU for all the tablets prepared originally from granules, in 0.1 M HCl 
medium. Increasing the calcium carbonate levels from 10% (w/w) (F1) to 20% (w/w) (F2) 
caused a significant (P<0.05) decrease in tablet swelling at all the time points, however, 
increasing the sodium carbonate level did not cause a significant (P>0.05) effect on the swelling 
of F3 and F4 tablets. Figure 5b reveals images of F2 and F5 tablets (as examples) during their 
swelling characterization test for 24 hours. 
F2 tablets floated for >24 hours while F1 tablets floated for only >5 hours, causing the upper 
tablet surface of the F1 tablet to became available for DMU after sinking, and the tablet 
showed great swelling by the end of the experiment. Although F3 (10% w/w) and F4 (20% w/w) 
tablets based on the sodium carbonate as the gassing agent floated >12 and >24 hours, 
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respectively (Table 4), the DMU results were almost the same. The results for the F3 and F4 
tablets (Figure 5a) show a continuous increase in swelling rate only up to 12 hours, which could 
justify the absence of a significant (P>0.05) difference between the F3 and F4 formulations. 
The non-floating  F5 tablets remained under the surface of the dissolution medium for the 
entire period of the experiment and demonstrated a significantly higher (P<0.05) swelling rate 
profile at all the time points compared to F1 and F2 tablets based on calcium carbonate as the 
gassing agent except at the late time points (8-12 hours) of F1 tablets. However, this difference 
at all the time points was not significant (P>0.05) for F3 and F4 tablets based on sodium 
carbonate except at 0.5 hour time point. As mentioned earlier, sodium carbonate is a stronger 
alkaline material than calcium carbonate which might explain the ability of the F3 and F4 
tablets to swell at an almost similar rate to the F5 tablets even after the long period of floating. 
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Figure 5: a Percentage of dissolution medium uptake for F1, F2, F3, F4, and F5 tablets (prepared 
originally from granules) in 0.1 M HCl medium. The data represents the mean ± SD of three 
determinations. For formulation composition, refer to Table 1. b: Images of F2 and F5 tablets during 
their swelling for 24 hours. 
 
Figure 6 shows the percentage of mass loss for all the tablets prepared originally from granules. 
Increasing the gassing agent concentration of both calcium carbonate and sodium carbonate 
from 10% to 20% (w/w) significantly (P<0.05) increased  the mass loss at all the time points. 
The non-floating F5 tablets demonstrated the lowest mass loss percentage profile and their 
results, at all the time points, were significantly (P<0.05) lower than all other formulations 
except F3. Our previous study reported a higher effervescence effect due to a higher gassing 
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agent level, which will liberate more carbon dioxide bubbles that enhance erosion of the 
matrix.20 
 
Figure 6: Percentage of mass loss for F1, F2, F3, F4, and F5 tablets (prepared originally from granules) 
in 0.1 M HCl medium. The data represents the mean ± SD of three determinations. For formulation 
composition, refer to Table 1. 
 
 
In vivo pharmacokinetic study 
Tablets manufactured from granules with 20% (w/w) calcium carbonate (F2) were selected for 
further in vivo evaluation as these were promising with respect to their floating lag time (~ 
7min), floating duration (>24 hours), swelling ability, and sustained drug release rate.  
Pentoxifylline is completely absorbed from the gastrointestinal tract when given either in the 
form of sustained release tablets or immediate release capsules; however, its bioavailability 
averages only 20% to 30% due to extensive first pass metabolism.52 No advantage is expected 
from a comparative in vivo evaluation between non-floating sustained release tablets (F5) and 
the selected floating tablets (F2) (as no tablet images have been taken inside rats), hence F2 
floating tablets only were chosen for this in vivo study. However, it was a challenge using this 
highly soluble model drug, pentoxifylline, in the designed floating tablets with sustaining the 
drug release which is the main aim of this research. Therefore, it was worth preliminary 
investigating the ability of the designed floating formulation (F2) for improvements to 
pentoxifylline pharmacokinetic parameters as a controlled release dosage form. Further in vivo 
research is required in the future to confirm this preliminary in vivo data explanation. 
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An in vivo study of the F2 floating tablets and a reference solution of pentoxifylline were 
investigated following oral administration of 5.75±0.15 mg in rats. Drug plasma levels were 
determined by HPLC-MS/MS, and the regression equation was y = 0.0251x - 0.000893 
(r=0.9993) for pentoxifylline with a linear concentration of 4 – 400 ng/mL. The retention time 
was 0.45 and 0.30 min for pentoxifylline and the internal standard, respectively.  
The average plasma concentration-time profiles for the two formulations are shown in Figure 
7, and the pharmacokinetic parameters are shown in Table 6. The maximum plasma 
concentrations for the F2 tablets and the reference solution were 945.32 and 2552.30 ng/mL, 
respectively, and these were achieved at 1.58 and 0.50 h, respectively. Compared to the 
reference solution, the Cmax of the tablets decreased significantly (p<0.05), and the Tmax was 
prolonged significantly (p<0.05). Moreover, the half-life (t1/2) value increased significantly 
(p<0.05) from 0.29 to 0.61 h for the tablets in comparison with the solution; thus indicating 
the sustained-release behaviour of the F2 floating tablets.   
The relative bioavailability (F) of the tablets compared to the reference solution was 80.75%. 
This could be due to the significant (p<0.05) reduction in the AUC0-∞ value of the F2 tablets in 
comparison with the reference solution, which were 2368.11 and 2932.53 ng h/mL, 
respectively.  
The results of in vivo studies demonstrated that the formulation, F2, did show different 
pharmacokinetics respect to the solution, however, it can not be stated that it is 
gastroretentive. It can be only hypothesized from the in vitro data in a simulated gastric fluid. 
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Figure 7: Average pentoxifylline plasma concentration-time curve following oral administration of F2 
floating tablets and a reference solution in rats. The data represents the mean ± SD of six 
determinations. 
 
Table 6: Pharmacokinetic parameters of pentoxifylline F2 tablets and reference solution. 
Formulation Ke (h-1) t1/2 (h) Cmax (ng/ml) Tmax (h) AUC0-∞(ng h/ml) 
F2 floating tablets 1.25±0.48 0.61±0.19 945.32±442.87 1.58±0.66 2368.11±712.59 
Reference solution  2.42±0.21 0.29±0.03 2552.30±110.85 0.50±0.00 2932.53±351.23 
The data represent mean ± SD of six determinations. For F2 formulation composition refer to Table 1 
 
Conclusions 
Effervescent pentoxifylline floating tablets were successfully prepared using a (1:1) binary 
mixture of hydroxyethyl cellulose and sodium alginate polymeric mixture based on either 
calcium carbonate or sodium carbonate as the gas-forming agent. All tablets prepared via wet 
granulation showed acceptable physicochemical properties by metting the BP requirements of 
friability, weight and drug content uniformity. Increasing the concentration of the gassing 
agent decreased the floating lag time results for tablets based on calcium carbonate and 
increased it for those based on sodium carbonate. All the tablets floated on the surface of the 
dissolution medium and drug release was sustained over 24 hours. Tablets prepared with 20% 
(w/w) calcium carbonate were promising with respect to their floating lag time, floating 
duration, swelling ability, sustained drug release rate, and an in vivo study of these tablets 
showed sustained-release behaviour.  
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